mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease

Mitochondrial disease associated with the pathogenic m.3243A>G variant is a common, clinically heterogeneous, neurogenetic disorder. Using multiple linear regression and linear mixed modelling, we evaluated which commonly assayed tissue (blood N = 231, urine N = 235, skeletal muscle N = 77) represents the m.3243A>G mutation load and mitochondrial DNA (mtDNA) copy number most strongly associated with disease burden and progression. m.3243A>G levels are correlated in blood, muscle and urine (R2 = 0.61–0.73). Blood heteroplasmy declines by ~2.3%/year; we have extended previously published methodology to adjust for age. In urine, males have higher mtDNA copy number and ~20% higher m.3243A>G mutation load; we present formulas to adjust for this. Blood is the most highly correlated mutation measure for disease burden and progression in m.3243A>G‐harbouring individuals; increasing age and heteroplasmy contribute (R2 = 0.27, P < 0.001). In muscle, heteroplasmy, age and mtDNA copy number explain a higher proportion of variability in disease burden (R2 = 0.40, P < 0.001), although activity level and disease severity are likely to affect copy number. Whilst our data indicate that age‐corrected blood m.3243A>G heteroplasmy is the most convenient and reliable measure for routine clinical assessment, additional factors such as mtDNA copy number may also influence disease severity.

[1]  Robert W. Taylor,et al.  Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors , 2018, Annals of clinical and translational neurology.

[2]  P. Laforêt,et al.  Prediction of long‐term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with the mitochondrial encephalomyopathy, lactic acidosis and stroke‐like episodes syndrome , 2017, European journal of neurology.

[3]  M. Picard,et al.  Disentangling (Epi)Genetic and Environmental Contributions to the Mitochondrial 3243A>G Mutation Phenotype: Phenotypic Destiny in Mitochondrial Disease? , 2016, JAMA neurology.

[4]  H. Majima,et al.  Clinical Phenotype and Segregation of Mitochondrial 3243A>G Mutation in 2 Pairs of Monozygotic Twins. , 2016, JAMA neurology.

[5]  Robert W. Taylor,et al.  Three families with ‘de novo’ m.3243A > G mutation , 2016, BBA clinical.

[6]  Robert W. Taylor,et al.  Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease , 2015, Annals of neurology.

[7]  Chikaaki Motoda,et al.  Impaired respiratory function in MELAS-induced pluripotent stem cells with high heteroplasmy levels , 2015, FEBS open bio.

[8]  Robert W. Taylor,et al.  Accurate Measurement of Mitochondrial DNA Deletion Level and Copy Number Differences in Human Skeletal Muscle , 2014, PloS one.

[9]  S. Dimauro,et al.  Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers , 2014, Neurology.

[10]  M. Zeviani,et al.  Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy , 2013, Brain : a journal of neurology.

[11]  Robert W. Taylor,et al.  Disease progression in patients with single, large-scale mitochondrial DNA deletions , 2013, Brain : a journal of neurology.

[12]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[13]  G. Comi,et al.  The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender? , 2014, Journal of Neurology.

[14]  A. Suomalainen,et al.  Tissue- and cell-type–specific manifestations of heteroplasmic mtDNA 3243A>G mutation in human induced pluripotent stem cell-derived disease model , 2013, Proceedings of the National Academy of Sciences.

[15]  Y. Qi,et al.  Wild-Type Mitochondrial DNA Copy Number in Urinary Cells as a Useful Marker for Diagnosing Severity of the Mitochondrial Diseases , 2013, PloS one.

[16]  Robert W. Taylor,et al.  The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation—implications for diagnosis and management , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  H. Tse,et al.  Urine as a source of stem cells. , 2013, Advances in biochemical engineering/biotechnology.

[18]  Guo-Qing Chen,et al.  Effects of exercise intensity on copy number and mutations of mitochondrial DNA in gastrocnemus muscles in mice. , 2012, Molecular medicine reports.

[19]  R. Rodenburg,et al.  Erratum to: Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation , 2012 .

[20]  S. Dimauro,et al.  Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype , 2011, Neurology.

[21]  D. Turnbull,et al.  Habitual Physical Activity in Mitochondrial Disease , 2011, PloS one.

[22]  S. Dimauro,et al.  Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS , 2009, American journal of medical genetics. Part A.

[23]  D. Turnbull,et al.  URINE HETEROPLASMY IS THE BEST PREDICTOR OF CLINICAL OUTCOME IN THE m.3243A>G mtDNA MUTATION , 2009, Neurology.

[24]  P. Chinnery,et al.  Pathogenic Mitochondrial DNA Mutations Are Common in the General Population , 2008, American journal of human genetics.

[25]  H. Rajasimha,et al.  Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G mutation in blood. , 2008, American journal of human genetics.

[26]  D. Turnbull,et al.  Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement , 2006, Neuropathology and applied neurobiology.

[27]  Robert W. Taylor,et al.  Depletion of mitochondrial DNA in leucocytes harbouring the 3243A→G mtDNA mutation , 2006, Journal of Medical Genetics.

[28]  D. Turnbull,et al.  Mitochondrial disease in adults: A scale to monitor progression and treatment , 2006, Neurology.

[29]  W. Cheng,et al.  Alteration in the copy number of mitochondrial DNA in leukocytes of patients with mitochondrial encephalomyopathies , 2006, Acta neurologica Scandinavica.

[30]  S. Rahman,et al.  Decrease of 3243 A-->G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. , 2001, American journal of human genetics.

[31]  A. Quigley,et al.  Detection of MELAS A3243G point mutation in muscle, blood and hair follicles , 1998, Journal of the Neurological Sciences.

[32]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[33]  Charles E. Brown.  Applied Multivariate Statistics in Geohydrology and Related Sciences , 1998 .

[34]  D. Turnbull,et al.  Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. , 1997, Brain : a journal of neurology.

[35]  G. Attardi,et al.  Relationship of genotype to phenotype in fibroblast-derived transmitochondrial cell lines carrying the 3243 mutation associated with the MELAS encephalomyopathy: shift towards mutant genotype and role of mtDNA copy number. , 1996, Human molecular genetics.

[36]  I. Nonaka,et al.  A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies , 1990, Nature.

[37]  S. Dimauro,et al.  Mitochondrial diseases. , 1989, Neurologic clinics.

[38]  W. Holtzman,et al.  The unbiased estimate of the population variance and standard deviation. , 1950, The American journal of psychology.

[39]  G. Kesteven,et al.  The Coefficient of Variation , 1946, Nature.

[40]  the original work is properly cited. , 2022 .